Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists
暂无分享,去创建一个
Shan Xie | Daniel C Javitt | D. Javitt | H. Sershen | R. Suckow | A. Balla | Andrea Balla | Sarah Burch | Ray Suckow | Henry Sershen | S. Xie | Sarah Burch
[1] Charles R. Yang,et al. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. , 2002, Journal of neurophysiology.
[2] M. Laruelle. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[3] D. Javitt,et al. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial , 1996, Biological Psychiatry.
[4] M Laruelle,et al. Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.
[5] P. Renshaw,et al. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. , 1996, The American journal of psychiatry.
[6] M Laruelle,et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.
[7] J. Krystal,et al. IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans , 2000, Biological Psychiatry.
[8] Douglas W. Jones,et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[9] D. Javitt,et al. Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.
[10] D. Javitt,et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia , 2004, Biological Psychiatry.
[11] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] P. Contreras. D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia , 1990, Neuropharmacology.
[14] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[15] D. Charney,et al. Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.
[16] R. Roth,et al. Subchronic Phencyclidine Administration Increases Mesolimbic Dopaminergic System Responsivity and Augments Stress- and Psychostimulant-Induced Hyperlocomotion , 1998, Neuropsychopharmacology.
[17] Nicholas Lange,et al. D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.
[18] A. Carlsson,et al. Glycine and D-serine decrease MK-801-induced hyperactivity in mice , 2005, Journal of Neural Transmission.
[19] J. Coyle,et al. Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] A. Malhotra,et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.
[21] D. Javitt,et al. The role of excitatory amino acids in neuropsychiatric illness. , 1990, The Journal of neuropsychiatry and clinical neurosciences.
[22] Hans Forssberg,et al. Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] V. Ognyanov,et al. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. , 2001, Molecular pharmacology.
[24] D. Javitt,et al. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse , 1997, Psychopharmacology.
[25] D. Javitt,et al. Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.
[26] R. Elliott,et al. Effects of methylphenidate on spatial working memory and planning in healthy young adults , 1997, Psychopharmacology.
[27] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[28] D. Javitt,et al. Chronic high-dose glycine nutrition: effects on rat brain cell morphology , 2001, Biological Psychiatry.
[29] M. Mishina,et al. Hyperfunction of Dopaminergic and Serotonergic Neuronal Systems in Mice Lacking the Nmda Receptor ⑀1 Subunit , 2022 .
[30] A. Belger,et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions , 2000, Biological Psychiatry.
[31] Adrian M. Owen,et al. Methylphenidate Enhances Working Memory by Modulating Discrete Frontal and Parietal Lobe Regions in the Human Brain , 2000, The Journal of Neuroscience.
[32] F. Carone,et al. D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis. , 1975, Archives of pathology.
[33] M. Laruelle,et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.
[34] T. Goldberg,et al. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. , 1991, The American journal of psychiatry.
[35] P B Hoffer,et al. Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.
[36] A. Lajtha,et al. Antagonism of phencyclidine-induced hyperactivity by glycine in mice , 1986, Neurochemical Research.
[37] D. Javitt,et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.
[38] T. F. Burke,et al. [3H]MK-801 binding to well-washed rat brain membranes following cessation of chronic phencyclidine treatment , 1995, Pharmacology Biochemistry and Behavior.
[39] R. Roth,et al. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. , 1997, Science.
[40] W. Gentry,et al. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[41] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[42] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[43] P. O’Donnell,et al. D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. , 2001, Cerebral cortex.
[44] Tamara Hershey,et al. Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.
[45] A. Malhotra,et al. Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers , 1998, Biological Psychiatry.
[46] D. Javitt,et al. Continuous Phencyclidine Treatment Induces Schizophrenia-Like Hyperreactivity of Striatal Dopamine Release , 2001, Neuropsychopharmacology.
[47] J. Meyer,et al. A NEW DRUG CAUSING SYMPTOMS OF SENSORY DEPRIVATION Neurological, Electroencephalographic and Pharmalogical Effects of Sernyl , 1959 .
[48] A. Grace,et al. Glutamatergic Afferents from the Hippocampus to the Nucleus Accumbens Regulate Activity of Ventral Tegmental Area Dopamine Neurons , 2001, The Journal of Neuroscience.
[49] Holly Moore,et al. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia , 1999, Biological Psychiatry.
[50] J. Coyle,et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.
[51] D. Javitt,et al. Non-competitive regulation of phencyclidine/σ-receptors by the N-methyl-d-aspartate receptor antagonist d-(−)-2-amino-5-phosphonovaleric acid , 1987, Neuroscience Letters.
[52] D. Javitt,et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.
[53] D. Javitt,et al. Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release , 2003, Neuropsychopharmacology.
[54] T. Svensson. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs , 2000, Brain Research Reviews.
[55] J. Lieberman,et al. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases , 1999, Biological Psychiatry.
[56] M. Laruelle,et al. Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.
[57] Joseph T. Coyle,et al. The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.
[58] E. Abercrombie,et al. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats , 1996, Brain Research Bulletin.
[59] G. A. Kevetter,et al. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex , 1998, Journal of neuroscience research.
[60] A. Brown,et al. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes , 2001, Neuropharmacology.
[61] D. Javitt,et al. High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum. , 1999, The international journal of neuropsychopharmacology.
[62] Marc Laruelle,et al. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.
[63] A. Lajtha,et al. Phencyclidine-Induced Dysregulation of Dopamine Response to Amphetamine in Prefrontal Cortex and Striatum , 2001, Neurochemical Research.
[64] R. Roth,et al. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits , 1999, Neuroscience.
[65] Ganote Ce,et al. D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis. , 1975 .
[66] A. Lajtha,et al. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors , 1999, Biological Psychiatry.
[67] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[68] D. Javitt. Glycine modulators in schizophrenia. , 2002, Current opinion in investigational drugs.